Browse News

Found 69,578 articles

• Marinus Pharmaceuticals Receives Positive CHMP Opinion for ZTALMY® (ganaxolone) for the Adjunctive Treatment of Seizures Associated With CDKL5 Deficiency Disorder

  5/26/2023

  Marinus Pharmaceuticals, Inc. announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending the approval of ZTALMY® oral suspension for the adjunctive treatment of epileptic seizures associated with cyclin-dependent kinase-like 5 deficiency disorder in patients two to 17 years of age.

• Exact Sciences Presents New Long-Term Patient Outcomes in Multi-Cancer Early Detection and Breast Cancer Recurrence Testing at ASCO® 2023

  5/26/2023

  Exact Sciences Corp. announced that it will present 15 abstracts at the American Society of Clinical Oncology® Annual Meeting 2023, June 2-6, in Chicago, Illinois.

• Y-mAbs Announces Presentation of GD2-SADA Study at ASCO

  5/26/2023

  Y-mAbs Therapeutics, Inc. announced that a poster presentation featuring the design of its Phase 1 clinical trial, evaluating the Company’s Self-Assembly DisAssembly Pre-targeted Radioimmunotherapy Theranostic Platform for the treatment of certain GD2-positive solid tumors, including small cell lung cancer, sarcoma and malignant melanoma will be presented at the American Society of Clinical Oncology Annual Meeting to be held June 2-6, 2023 in Chicago, Illinois.

• Y-mAbs Announces Presentation of Naxitamab Data at ASCO

  5/26/2023

  Y-mAbs Therapeutics, Inc. announced that a poster presentation featuring interim clinical data on naxitamab, a recombinant, humanized anti-GD2 monoclonal antibody, in combination with granulocyte-macrophage colony-stimulating factor will be presented at the American Society of Clinical Oncology Annual Meeting to be held June 2-6, 2023, in Chicago, Illinois.

• Iovance Biotherapeutics Announces U.S. Food and Drug Administration Acceptance of the Biologics License Application of Lifileucel for the Treatment of Advanced Melanoma

  5/26/2023

  Iovance Biotherapeutics, Inc. announced that the U.S. Food and Drug Administration accepted its Biologics License Application for lifileucel for patients with advanced melanoma.

• Novavax's Nuvaxovid™ Receives Positive CHMP Opinion for Full Marketing Authorization for the Prevention of COVID in the EU

  5/26/2023

  Novavax, Inc. announced that Nuvaxovid™ has been recommended for full Marketing Authorization for use as a primary series in individuals aged 12 and older and as a booster in individuals aged 18 and older for the prevention of COVID-19 in the European Union following a positive opinion issued by the Committee for Medicinal Products for Human Use of the European Medicines Agency.

• Masimo Board of Directors Files Definitive Proxy and Issues Letter to Stockholders

  5/26/2023

  The Masimo Corporation Board of Directors issued a letter to stockholders in connection with its definitive proxy materials filed on May 24, 2023, and the Company’s Annual Meeting of Stockholders to be held on June 26, 2023.

• Biophytis has Filed with the French National Authority for Health (HAS) an Application for Early Access Authorisation (EAA) for Sarconeos (BIO101) in the Treatment of Severe Forms of COVID-19

  5/26/2023

  Biophytis SA announced that it has filed, through its pharmaceutical partner Intsel Chimos, an application for Early Access Authorisation in France with the French National Authority for Health for the use of Sarconeos [1] in the treatment of adult patients with a severe form of COVID-19, who are at risk of developing a critical form of the disease and for whom therapeutic alternatives are not appropriate.

• CHMP Adopts Positive Opinion to Extend the Use of Veklury® (Remdesivir) to Treat COVID-19 in People With Severe Renal Impairment, Including Those on Dialysis

  5/26/2023

  Gilead Sciences, Inc. announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency granted a positive opinion for the use of Veklury® in COVID-19 patients with severe renal impairment, including those on dialysis.

• Infectious Disease Diagnostics Market to Grow at 6.8% CAGR to be Worth $37.94Bn, Globally, by 2028 - Exclusive Report by The Insight Partners

  5/26/2023

  The Insight Partners published latest research study on "Infectious Disease Diagnostics Market Forecast to 2028- COVID-19 Impact, and Global Analysis

• Pharmacogenomics Market to Grow at 10.3% CAGR to be Worth $14.10Bn, Globally, by 2028 - Exclusive Report by The Insight Partners

  5/26/2023

  The Insight Partners published latest research study on "Pharmacogenomics Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Technology

• Mammography Systems Market to Grow at 7.4% CAGR to be Worth $3.79Bn, Globally, by 2027 - Exclusive Report by The Insight Partners

  5/26/2023

  According to the new market research report "Mammography Systems Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Product (Analog Systems, Full Field Digital Mammography Systems, Breast Tomosynthesis Systems)

• Coagulation Analyser Market (Product, Test, Technology) Size to Exceed $5.91057 Bn, Globally, by 2028 | Growing at 5.9% CAGR | Exclusive Report by The Insight Partners

  5/26/2023

  The Insight Partners published latest research study on “Coagulation Analyser Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by Product, Test, Technology, End Users, and Geography,

• 6.2% CAGR, X-Ray Photoelectron Spectroscopy Market Size to Gain $896.90 Mn by 2027, Globally - Exclusive Report by The Insight Partners

  5/26/2023

  According to The Insight Partners new research study titled "X-Ray Photoelectron Spectroscopy Market Size, Share, Growth and Forecast to 2027 – COVID-19 Impact and Global Analysis

• Immunodiagnostics Market (Product, Clinical Indication) to Gain $29.52 Bn by 2028 with Booming CAGR Value of 7.4% | The Insight Partners

  5/26/2023

  According to The Insight Partners latest study on "Immunodiagnostics Market Size, Share, Growth, Trends and Forecast to 2028 – COVID-19 Impact and Global Analysis

• Diagnostic Imaging Market to Grow at 5.8% CAGR to be Worth $53.41Bn by 2028 Research Report Published by The Insight Partners

  5/26/2023

  The Insight Partners published latest research study on "Diagnostic Imaging Market Forecast to 2028 – COVID-19 Impact and Global Analysis

• HPV Vaccine Market: 5.73Bn by 2028, Human Papillomavirus Vaccine Market (Type, Dosage) Growing at 5% CAGR Lead by 9-Valent HPV Vaccine Segment, Global Analysis by The Insight Partners

  5/26/2023

  The Insight Partners published latest research study on “Human Papillomavirus (HPV) Vaccine Market Size, Share, Growth, Revenue, Trends, Forecast to 2028 - COVID-19 Impact and Global Analysis By Type (9-Valent HPV Vaccine, Quadrivalent HPV Vaccine

• Exoskeleton Robotic System Market (Type, Application) Size Worth USD 4.22Bn, Globally, by 2028 Growing at 23.0% CAGR | Exclusive Report by The Insight Partners

  5/26/2023

  According to our new research study on "Exoskeleton Robotic System Market Forecast to 2028 – COVID-19 Impact and Global Analysis

• Diabetic Foot Ulcer Treatment Market (Type, Ulcer Type) to Grow at 7.9% CAGR During (2021-2028) Global Analysis by TheInsightPartners.com

  5/26/2023

  According to our new research study on "Diabetic Foot Ulcer Treatment Market to 2027 – Global Analysis and Forecast – by Type, Ulcer Type, and End User," the market was valued at US$ 4,580.24 million in 2021 and is projected to reach US$ 7,793.83 million by 2028; it is expected to grow at a CAGR of 7.9% during 2021–2028

• Neuromodulation Market to Grow at 10.3% CAGR During (2020-2027) Global Analysis by The Insight Partners

  5/26/2023

  According to The Insight Partners study on "Neuromodulation Market to 2027 – Global Analysis and Forecast – by Technology, Application and End User" the neuromodulation market was valued at US$ 7, 613.45 million